Zydus Lifesciences Limited
Read Time:11 Second
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled “Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg”. |SUBJECT: Press Release
Happy
0
0 %
Sad
0
0 %
Excited
0
0 %
Sleepy
0
0 %
Angry
0
0 %
Surprise
0
0 %
More Stories
Bhagiradha Chemicals & Industries Limited
Bhagiradha Chemicals & Industries Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI (Listing Obligations and...
HFCL Limited
HFCL Limited has informed the Exchange about Sale of HFCL Limited s Thermal Weapon Sights ( TWS ) business to...
Oil & Natural Gas Corporation Limited
Oil & Natural Gas Corporation Limited has informed the Exchange about Corrigendum in respect of Announcement Appointment of Director (Finance)...
HFCL Limited
HFCL Limited has informed the Exchange about Sale of up to 80% of the paid-up share capital of Raddef Private...
Amit Spinning Industries Limited
Amit Spinning Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. |SUBJECT:...
Akums Drugs and Pharmaceuticals Limited
Intimation of Schedule of the Investor/Analysts Meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
Average Rating